kynostatin 272 has been researched along with ritonavir in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (42.86) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blum, LE; Clemente, JC; Dunn, BM; Goodenow, MM; Hemrajani, R | 1 |
| Ami, E; Hamada, Y; Hayashi, Y; Hidaka, K; Kimura, T; Kiso, Y; Nakahara, K; Nakatani, S; Nguyen, JT; Sato, A | 1 |
| Ami, E; Hamada, Y; Hayashi, Y; Hidaka, K; Hori, Y; Kimura, T; Kiso, Y; Nagai, A; Nakahara, K; Nakatani, S; Nguyen, JT; Ohnishi, N; Sato, A | 1 |
| Anderson, B; Erickson, JW; Gulnik, SV; Liu, B; Mitsuya, H; Suvorov, LI; Yu, B | 1 |
| Maeda, Y; Mitsuya, H; Uchida, H | 1 |
| Aquaro, S; Caliò, R; Davis, DA; Humphrey, RW; Newcomb, FM; Perno, CF; Yarchoan, R | 1 |
| Lu, Y; Wang, S; Yang, CY | 1 |
7 other study(ies) available for kynostatin 272 and ritonavir
| Article | Year |
|---|---|
Secondary mutations M36I and A71V in the human immunodeficiency virus type 1 protease can provide an advantage for the emergence of the primary mutation D30N.
Topics: Alanine; Anti-HIV Agents; Asparagine; Aspartic Acid; Binding Sites; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Indinavir; Isoleucine; Kinetics; Methionine; Mutagenesis, Site-Directed; Nelfinavir; Ritonavir; Valine | 2003 |
Synthesis and antiviral property of allophenylnorstatine-based HIV protease inhibitors incorporating D-cysteine derivatives as P2/P3 moieties.
Topics: Amides; Cell Line; Cysteine; HIV; HIV Protease Inhibitors; Humans; Models, Molecular; Phenylbutyrates; Thiazoles | 2007 |
Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.
Topics: Amino Acids; Drug Resistance, Viral; HIV Protease; HIV Protease Inhibitors; HIV-1; Models, Molecular; Mutation; Phenylbutyrates; Stereoisomerism; Structure-Activity Relationship; Thiazoles | 2008 |
Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure.
Topics: Amino Acid Sequence; Binding Sites; Carbamates; Cloning, Molecular; Drug Resistance, Microbial; HIV Protease; HIV Protease Inhibitors; HIV-1; Indinavir; Isoquinolines; Kinetics; Methylurea Compounds; Mutagenesis, Site-Directed; Oligopeptides; Point Mutation; Pyridines; Quinolines; Recombinant Proteins; Saquinavir; Structure-Activity Relationship; Thiazoles; Valine | 1995 |
HIV-1 protease does not play a critical role in the early stages of HIV-1 infection.
Topics: Chloramphenicol O-Acetyltransferase; HeLa Cells; HIV Infections; HIV Protease; HIV Protease Inhibitors; HIV-1; Humans; Oligopeptides; Ritonavir; Saquinavir | 1997 |
Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus.
Topics: Anti-HIV Agents; Cell Line; Cells, Cultured; HIV Core Protein p24; HIV Protease Inhibitors; HIV-1; Humans; Macrophages; Monocytes; Oligopeptides; Reverse Transcriptase Inhibitors; Ritonavir; Saquinavir; Zidovudine | 1998 |
Binding free energy contributions of interfacial waters in HIV-1 protease/inhibitor complexes.
Topics: Binding Sites; Computer Simulation; Crystallization; HIV Protease; HIV Protease Inhibitors; Kinetics; Models, Chemical; Models, Molecular; Oligopeptides; Protein Binding; Protein Conformation; Ritonavir; Thermodynamics; Water | 2006 |